Anticancer Therapies – Products

Product News
Curiox Biosystems To Advance Next-Generation Cancer Cell Therapies Through Collaboration With Leading Cancer Researcher
Curiox Biosystems announces its collaboration with Dr. Marco Ruella, an assistant professor of medicine at the Perelman School of Medicine, to support efforts in the development of next-generation cancer cell therapies.

Whitepaper
Antibody–Drug Conjugates: A Novel Paradigm for Cancer Therapy
This whitepaper highlights the key molecular components of ADCs and the challenges and opportunities for their future development.

Product News
Accelerating Cell Therapies with Manufacturing Breakthrough
Thermo Fisher announced a first of its kind technology to help accelerate the molecule-to-market process by driving efficiency and reducing manufacturing costs.

Product
Advertisement
Comprehensive CAR-T Therapy Solutions
With six CAR-T drugs currently approved by the FDA and more to follow, Sino Biological has committed to developing reagents and services to support our clients in CAR development, CAR-T preparation and lentivirus packaging, CAR-T cell expansion, and CAR-T quality control.

Product
Advertisement
GMP-Grade Cytokines for Cell Therapy Research
Sino Biological performs extensive quality control tests to ensure that GMP-grade cytokines meet rigorous quality standards, offering a range of GMP-grade cytokines

Product
Advertisement
View the Webinar Focus on Cytokines Therapies
During this webinar, we will provide a comprehensive overview of several cytokine therapy approaches, development, and clinical application. We will further discuss how Sino Biological can assist in cancer immunotherapy research.

Whitepaper
Tumor Exosomes: A Messenger for Cancer Progression
This whitepaper explores the role of extracellular vesicles in cell-to-cell communication during cancer progression. It also highlights a range of high-quality recombinant proteins, antibodies and cytokines and to support exosome research.

Whitepaper
How To Accelerate and De-Risk Drug Development in Oncology
Although there are initiatives to de-risk the drug development process, continually applying the same tools and approaches is unlikely to lead to innovative, first- or best-in-class targets and transformative progress.

Product News
Oncodesign Services Announce Access to ImaginAb’s CD8 ImmunoPET™ Technology
Oncodesign Services announces the execution of a Preclinical License and Supply Agreement with ImaginAb Inc. for the use of their investigational CD8 ImmunoPET™ (89Zr crefmirlimab berdoxam) technology.

Compendium
Cell and Gene Therapies: Innovations and Applications
Cell and gene therapies seek to correct the root cause of an illness at the molecular level. These game-changing medicines are reshaping how we address previously untreatable illnesses – transforming people’s lives.
Advertisement